英官方研究:辉瑞及阿斯利康疫苗对预防长者感染新冠高度有效
英国公共卫生部(PHE)调查显示,辉瑞(PFE.US)及牛津大学-阿斯利康(AZN.US)疫苗在减少英国长者新冠感染及重症上高度有效,入院治疗减少逾80%。
据PHE自1月起收集数据所得,对逾八十岁人士,接种以上两种其一单剂疫苗後三至四周,在预防入院治疗上有效率逾80%。法国及德国现正考虑撤回阻止对65岁或以上长者接种阿斯利康疫苗的安排。
英国卫生大臣夏国贤形容有关研究结果是「极好的新闻」。研究补充,两种疫苗在减少70岁以上长者感染新冠肺炎上高度有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.